Thursday, September 21, 2017 2:17:58 PM
so you are saying NW invested 180 million then sabotaged his own investment with Phase V and investigation so he can lose all his monies to kill NWBO technology for BP? Well sounds like he is the dumbest fund manager ever. imho... but what do I know he gave them money to build Sawston so it can never be used... huh??? I don't get the logic here.. He could of just shorted the stock and gotten the same result. instead he is the brunt of harsh criticism for his investing in NWBO by all his shareholders and they are questioning his leadership?
Now why he has not stayed on top of management is a good question cause the premise of his fund management is they are very engaged with management of all their companies so they can understand the true value of their assets. They clearly have stayed away from NWBO management and NWBO has never come back with results of investigation so that is a dilemma.. I totally believe NWBO is honest company but paranoid for good reason, unfortunately that is not good for any relationship, lack of trust & communication. Hopefully topline will be presented soon and everyone validated for their belief in Dr.Liau, DC-Vax and NWBO management for sticking with the trials!
Now why he has not stayed on top of management is a good question cause the premise of his fund management is they are very engaged with management of all their companies so they can understand the true value of their assets. They clearly have stayed away from NWBO management and NWBO has never come back with results of investigation so that is a dilemma.. I totally believe NWBO is honest company but paranoid for good reason, unfortunately that is not good for any relationship, lack of trust & communication. Hopefully topline will be presented soon and everyone validated for their belief in Dr.Liau, DC-Vax and NWBO management for sticking with the trials!
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
